ePrints

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score

Lookup NU author(s): Professor John IsaacsORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2020 Future Medicine Ltd.. All rights reserved.Aim: TNF inhibitor drugs are a treatment option for rheumatoid arthritis, but response is not universal. Response is typically measured using the composite 4-component (4C) disease activity score 28 (DAS28) which contains more subjective measures. This study used a validated 2-component (2C) DAS28 score to determine whether SNPs associated with response were replicated in the UK population. Materials and methods: A literature review identified TNF inhibitor response SNPs. Linear regression was conducted to replicate associations with 4C or 2C-DAS28 response. Results: Eighteen independent SNPs were analyzed in 1828 patients. One and four associations with 4C and 2C-DAS28 response respectively were identified (p ≤ 0.05). Conclusion: Further genetic associations were replicated using the 2C-DAS28 which may reflect the objective nature of 2C-AS28.

Publication metadata

Author(s): Gilani SSA, Nair N, Plant D, Hyrich K, Morgan AW, Morris AP, Wilson AG, Isaacs JD, Barton A, Bluett J

Publication type: Article

Publication status: Published

Journal: Pharmacogenomics

Year: 2020

Volume: 21

Issue: 16

Pages: 1151-1156

Online publication date: 30/10/2020

Acceptance date: 27/03/2020

ISSN (print): 1462-2416

ISSN (electronic): 1744-8042

Publisher: Future Medicine Ltd.

URL: https://doi.org/10.2217/pgs-2020-0043

DOI: 10.2217/pgs-2020-0043

PubMed id: 33124499

Altmetrics

Share